← Back to Search

Rectus Sheath Block for Cystectomy

Phase 3
Waitlist Available
Led By Yar Yeap, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assess daily as yes/no
Awards & highlights

Study Summary

This trial will test four different methods of controlling pain during and after surgery for patients who are having their bladder removed.

Eligible Conditions
  • Cystectomy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~96 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and 96 hour for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
VAS score at 48 hour
VAS score at 72 hour
Secondary outcome measures
Ambulation Activity
Average Nausea score 1 hour
Average Nausea score 24 hour
+21 more

Trial Design

4Treatment groups
Active Control
Group I: Rectus Sheath BlockActive Control3 Interventions
2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected into 4 locations below the rectus abdominis muscle.
Group II: Surgeon InfiltrationActive Control2 Interventions
4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.
Group III: Thoracic epiduralActive Control2 Interventions
1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.
Group IV: Surgeon Infiltration with Liposomal Bupivacaine (LB)Active Control3 Interventions
3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
980 Previous Clinical Trials
983,141 Total Patients Enrolled
Yar Yeap, MDPrincipal Investigator - Indiana University Hospital
Indiana University
6 Previous Clinical Trials
530 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy
Yar Yeap 2019. "Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04300231.
All > Exparel
~29 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top